CN113164575A - 融合蛋白 - Google Patents

融合蛋白 Download PDF

Info

Publication number
CN113164575A
CN113164575A CN201980079296.1A CN201980079296A CN113164575A CN 113164575 A CN113164575 A CN 113164575A CN 201980079296 A CN201980079296 A CN 201980079296A CN 113164575 A CN113164575 A CN 113164575A
Authority
CN
China
Prior art keywords
fusion protein
leu
ile
asn
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980079296.1A
Other languages
English (en)
Chinese (zh)
Inventor
罗宾·沙托克
约恩·奥尔登
保罗·麦凯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Technology Innovation Co ltd
Original Assignee
Imperial Technology Innovation Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Technology Innovation Co ltd filed Critical Imperial Technology Innovation Co ltd
Publication of CN113164575A publication Critical patent/CN113164575A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980079296.1A 2018-10-17 2019-10-16 融合蛋白 Pending CN113164575A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816873.2 2018-10-17
GBGB1816873.2A GB201816873D0 (en) 2018-10-17 2018-10-17 Fusion protein
PCT/GB2019/052945 WO2020079427A1 (en) 2018-10-17 2019-10-16 Fusion protein

Publications (1)

Publication Number Publication Date
CN113164575A true CN113164575A (zh) 2021-07-23

Family

ID=64397455

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980079296.1A Pending CN113164575A (zh) 2018-10-17 2019-10-16 融合蛋白

Country Status (11)

Country Link
US (1) US20210386850A1 (https=)
EP (1) EP3866840A1 (https=)
JP (1) JP2022512754A (https=)
KR (1) KR20210114379A (https=)
CN (1) CN113164575A (https=)
AU (1) AU2019363172A1 (https=)
BR (1) BR112021007487A2 (https=)
CA (1) CA3116623A1 (https=)
GB (1) GB201816873D0 (https=)
WO (1) WO2020079427A1 (https=)
ZA (1) ZA202102533B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116240175A (zh) * 2023-02-28 2023-06-09 武汉科技大学 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN118414349A (zh) * 2021-12-20 2024-07-30 硕腾服务有限责任公司 用于在细胞膜上表达抗原的组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282161A (zh) * 2008-11-21 2011-12-14 国家科研中心 Piv-5和piv-2的f蛋白的突变蛋白
CN102282267A (zh) * 2008-11-21 2011-12-14 国家科研中心 Piv-5和piv-2的f蛋白的突变蛋白

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2378661A1 (en) * 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
MX2008000985A (es) * 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
EP2583974B1 (en) * 2011-10-21 2017-04-26 Technische Universität Dresden Pseudotyping of foamy viruses
ES2728248T3 (es) * 2012-01-24 2019-10-23 Univ Georgia Vacunas basadas en el virus paragripal 5
DK3247388T3 (da) * 2015-01-20 2025-12-22 Us Health Rekombinant human/bovin parainfluenzavirus 3 (b/hpiv3), der udtrykker et kimærisk rsv/bpiv3 f-protein, og anvendelser deraf
US10316295B2 (en) * 2015-12-17 2019-06-11 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102282161A (zh) * 2008-11-21 2011-12-14 国家科研中心 Piv-5和piv-2的f蛋白的突变蛋白
CN102282267A (zh) * 2008-11-21 2011-12-14 国家科研中心 Piv-5和piv-2的f蛋白的突变蛋白

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KATHRYN A GRA等: "The transmembrane domain sequence affects the structure and function of the Newcastle disease virus fusion protein", J VIRO, vol. 85, no. 7, pages 3486 - 3497, XP055646422, DOI: 10.1128/JVI.02308-10 *
MADELYN R SCHMIDT 等: "Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory", J VIROL., vol. 88, no. 17, pages 10165 - 10176, XP055264684, DOI: 10.1128/JVI.01250-14 *
TORU TAKIMO等: "Molecular mechanism of paramyxovirus bud", VIRUS RESEARCH, vol. 106, no. 2, pages 133 - 145, XP004657020, DOI: 10.1016/j.virusres.2004.08.010 *
李学仁;陈红;王文;邓瑶;齐香荣;高瑛瑛;孟昕;谭文杰;阮力;: "三个HIV-1广谱中和表位与HBV S抗原融合表达可诱导小鼠特异性抗体应答", 病毒学报, no. 04, pages 260 - 267 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116240175A (zh) * 2023-02-28 2023-06-09 武汉科技大学 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用
CN116240175B (zh) * 2023-02-28 2024-02-23 武汉科技大学 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用

Also Published As

Publication number Publication date
CA3116623A1 (en) 2020-04-23
WO2020079427A1 (en) 2020-04-23
JP2022512754A (ja) 2022-02-07
KR20210114379A (ko) 2021-09-23
BR112021007487A2 (pt) 2021-09-28
AU2019363172A1 (en) 2021-05-20
ZA202102533B (en) 2022-10-26
EP3866840A1 (en) 2021-08-25
GB201816873D0 (en) 2018-11-28
US20210386850A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
JP6170952B2 (ja) シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
Naskalska et al. Virus like particles as immunogens and universal nanocarriers
CN105263506B (zh) 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法
ES2869199T3 (es) Sistemas de expresión
US9296790B2 (en) Methods and compositions for protein delivery
CN113164575A (zh) 融合蛋白
WO2009115561A1 (fr) Polynucléotides et polypeptides chimériques permettant la sécrétion d'un polypeptide d'intérêt en association avec des exosomes et leur utilisation pour la production de compositions immunogènes
CN105792842A (zh) 埃巴病毒疫苗
KR20140107569A (ko) Ｈｐｖ에 대한 백신들
Martins et al. How promising are HIV-1-based virus-like particles for medical applications
KR20140132332A (ko) 프라임 부스트 백신용 수포성 구내염 바이러스
AU2015292261B2 (en) Constrained proteins and uses therefor
KR20160022919A (ko) 수포성 구내염 바이러스의 변형된 기질 단백질
BRPI0806336A2 (pt) lentivìrus pseudotipado com hemaglutinina da gripe e métodos de uso
US8889147B2 (en) DNA vaccine against multitypes of avian influenza viruses and influenza virus-like particles comprising adjuvant-fused M2 protein
Raska et al. Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses
US9150620B2 (en) Vaccine against multitypes of avian influenza viruses and uses thereof
KR20250029868A (ko) 재조합 변형 saRNA (VRP) 및 백시니아 바이러스 안카라 (MVA) 프라임-부스트 요법
KR20260048548A (ko) 베타-레트로바이러스 Gag를 포함하는 키메라 VLP 형성 폴리펩타이드
Pedro Molecular Determinants of Virus-Like Nanoparticle Assembly in vitro and in Animal Cell Culture

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723